Copper radionuclides and radiopharmaceuticals in nuclear medicine

doi:10.1016/S0969-8051(96)00130-8

Nuclear Medicine and Biology

Volume 23, Issue 8, November 1996, Pages 957-980

https://doi.org/10.1016/S0969-8051(96)00130-8 Get rights and content

Abstract

The chemistry, radiochemistry, radiobiology, and radiopharmacology of radiopharmaceuticals containing copper radionuclides are reviewed. Copper radionuclides offer application in positron emission tomography, targeted radiotherapy, and single photon imaging. The chemistry of copper is relatively simple and well-suited to radiopharmaceutical application. Current radiopharmaceuticals include biomolecules labelled via bifunctional chelators primarily based on cyclic polyaminocarboxylates and polyamines, and pyruvaldehyde-bis(N⁴-methylthiosemicarbazone) (PTSM) and its analogues. The chemistry of copper, of which only a fraction has yet been exploited, is likely to be applied more fully in the future.

References (210)

C.J Anderson et al.
Evaluation of copper-labeled bifunctional chelate-albumin conjugates for blood pool imaging
Nucl. Med. Biol.
(1993)
W.E Antholine et al.
Combined modality of 2-formylpyridine monothiosemicarbazonato copper (II) and radiation
Int. J. Radiat. Oncol. Biol. Phys.
(1981)
Y Arano et al.
Design, synthesis and ⁶⁴Cu labeling of fatty acid analogs containing dithiosemicarbazone chelate
Appl. Radiat. Isot.
(1989)
R.J Baker et al.
The effect of lipophilic substutuents on the biological properties of EDTA complexes containing paramagnetic metal ions
Nucl. Med. Biol.
(1987)
P.J Blower et al.
Thiolato-complexes of the transition metals
Coord. Chem. Rev.
(1987)
G Bormans et al.
A $^{62} Zn^{62} Cu$ generator for the routine production of ⁶²Cu-PTSM
Appl. Radiat. Isot.
(1992)
L.C Brown et al.
The separation and purification of carrier-free copper isotopes for medical use
Appl. Radiat. Isot.
(1972)
C.H Chan-Stier et al.
Reactions of bis(thiosemicarbazonato) copper(II) complexes with tumor cells and mitochondria
Bioinorg. Chem.
(1976)
D.A Cole et al.
The biological characteristics of a water-soluble porphyrin in rat lymph nodes
Nucl. Med. Biol.
(1990)
W.C Cole et al.
Serum stability of ⁶⁷Cu chelates: Comparison with ¹¹¹In and ⁵⁷Co
Nucl. Med. Biol.
(1986)

J Franz et al.

Labeling of antibodies with ⁶⁴Cu using a conjugate containing a macrocylic amine chelating agent

Nucl. Med. Biol.

(1987)

J.H Freedman et al.

Intracellular copper transport in cultured hepatoma cells

Biochem. Biophys. Res. Commun.

(1989)

P Gielow

Preparation of ⁶⁴Cu-labelled diethyl-HIDA

Appl. Radiat. Isot.

(1990)

M.A Green

A potential copper radiopharmaceutical for imaging the heart and brain: Copper-labeled pyruvaldehyde bis(N⁴-methylthiosemicarbazone)

Nucl. Med. Biol.

(1987)

E.L Hetherington et al.

The preparation of high specific activity copper-64 for medical diagnosis

Appl. Radiat. Isot.

(1986)

E John et al.

Structural characterisation of a metal-based perfusion tracer: Copper(II) pyruvaldehyde bis(N⁴-methylthiosemicarbazone)

Nucl. Med. Biol.

(1989)

E.K John et al.

Preparation and bio-distribution of copper-67 complexes with tetradentate Schiff-base ligands

J. Pharm. Sci.

(1994)

A Kraker et al.

Reaction of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato)copper(II) with Erhlich cells

J. Biol. Chem.

(1985)

S.-J Lau et al.

Ternary coordination complex between human serum albumin, copper(II), and L-histidine

J. Biol. Chem.

(1971)

W Levason et al.

The chemistry of copper and silver in their higher oxidation states

Coord. Chem. Rev.

(1987)

M.J Abrams et al.

Copper radiosensitizers

(1991)

M Akaboshi et al.

Lethal effects of the complex of bleomycin with high specific activity ⁶⁴Cu on Ehrlich ascites tumour cells

Annu. Rep. Res. Reactor Inst. Kyoto Univ.

(1978)

C.J Anderson et al.

Copper-64-labeled antibodies for PET imaging

J. Nucl. Med.

(1992)

C.J Anderson et al.

Optimization of the preparation of Cu-64-labeled monoclonal antibody (MAb) fragments (1A3-F(ab′)₂) for improved biodistribution

J. Nucl. Med.

(1993)

C.J Anderson et al.

Initial comparison of Cu-67 and Cu-64-labeled anti-colorectal carcinoma Mab 1A3 as agents for radioimmunotherapy in tumor-bearing hamsters

J. Nucl. Med.

(1994)

C.J Anderson et al.

Cu-64-TETA-D-Phe-1-Octreotide: A positron emitting somatostatin receptor imaging agent with receptor binding and renal clearance similar to In-111-DTPA-D-Phe-1-Octreotide

J. Nucl. Med.

(1994)

C.J Anderson et al.

Biodistribution in a tumorbearing animal model and metabolism of two Cu-64-labeled octreotide analogs

J. Nucl. Med.

(1995)

C.J Anderson et al.

Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab′)₂

J. Nucl. Med.

(1995)

C.J Anderson et al.

In vitro and in vivo evaluation of copper-64-octreotide conjugates

J. Nucl. Med.

(1995)

C.J Anderson et al.

Comparison of radioimmunotherapy (RIT) in colorectal tumor-bearing hamsters with Cu-64 and Cu-67-labeled Mab 1A3

J. Nucl. Med.

(1995)

W.E Antholine et al.

Immobile- and mobile-phase ESR spectroscopy of copper complexes: Studies on biologically interesting bis(thiosemicarbazonato) copper(II) chelates

Inorg. Chem.

(1984)

A.S Antisyshkina et al.

Crystal structures of tetrahydro borato(1,4,8,11-tetraazacyclotetradecane)copper(II) CuC₁₀H₂₄N⁴(BH₄)₂ and (5,7,12,14-tetramethyl-1,4,8,11-tetraazacyclononane)copper(II) CuC₁₄H₃₂N₄(BH₄)₂

Koord. Khim.

(1992)

S Apelgot et al.

Distribution of copper-64 in control mice and in mice bearing ascites Krebs tumor cells

Cancer Res.

(1981)

S Apelgot et al.

Differences in the consequences of the decay of radioactive ⁶⁴Cu atoms incorporated in cells under either in vitro or in vivo conditions

Radiat. Environ. Biophys.

(1987)

S Apelgot et al.

Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, ⁶⁴Cu and ⁶⁷Cu

Int. J. Radiat. Biol.

(1989)

J.W Babich et al.

An evaluation of Cu-64 pyruveldehyde bis(methylthiosemicarbazone) (PTSM) for the measurement of tissue perfusion

J. Nucl. Med.

(1989)

R.R Badertscher

Copper-64 as a radiopharmaceutical for canine prostate imaging

I.D Baerga et al.

Subcellular distribution of tissue radiocopper following intravenous administration of ⁶⁷ Cu-labeled Cu-PTSM

Nucl. Med. Biol.

(1991)

A.J Barnhart et al.

Examination of the effects of glutathione depletion on Cu(PTSM) biodistribution

J. Nucl. Med.

(1990)

R Beanlands et al.

Evaluation of Copper-62 PTSM as a myocardial flow tracer

J. Nucl. Med.

(1991)

R.S.B Beanlands et al.

The kinetics of copper-62-PTSM in the normal human heart

J. Nucl. Med.

(1992)

M.M Bernardo et al.

Evidence for a square scheme involving conformational intermediates in electron-transfer reactions of copper(II) systems

J. Am. Chem. Soc.

(1989)

S.J Berners-Price et al.

Phosphines and metal phosphine complexes: Relationship of chemistry to anticancer and other biological activity

Struct. Bonding

(1988)

M.J Bingham et al.

A comparison of copper uptake by liver plasma membrane vesicles and uptake by isolated cultured rat hepatocytes

Hepatology

(1994)

A Bischof Delaloye et al.

Cu-67-Anti-CEA MAB, a potential therapeutic agent: Biokinetic studies in patients with colon carcinoma

J. Nucl. Med.

(1994)

C.H Campbell et al.

Circulating ceruloplasmin is an important source of copper for normal and malignant animal cells

Biochim. Biophys. Acta

(1981)

L.R Chervu et al.

Dosimetry of copper radionuclides

J. Nucl. Med.

(1974)

M Chinol et al.

Evaluation of Cu-67 and Sm-153 immunoconjugates for tumor therapy

J. Nucl. Med.

(1992)

M Cikrt

Biliary excretion of ²⁰³Hg, ⁶⁵Cu, ⁵²Mn and ²¹⁰Pb in the rat

Br. J. Ind. Med.

(1972)

J.A Clarkson et al.

A new conformation and co-ordination mode for 1,4,7-trithiacyclo-nonane (9S3): Structure of [Cu₂(9S3)₃],(BF₄)₂ · H₂O

J. Chem. Soc. Chem. Commun.

(1989)

Cited by (368)

Biological activity of copper porphyrins
2024, Coordination Chemistry Reviews
The great possibility of synthetic modifications available in different aspects has elevated porphyrins as an appealing candidate for a plethora of applications. Accordingly, changes in coordination environment, peripheral substitutions, etc. have broadened the research to uplift the potential of porphyrins and metalloporphyrins. In this regard, it is undeniable that there are not many fields where porphyrins are not employed. Most importantly, this class of compounds has an overwhelming success in biological applications. Furthermore, being an essential part of the human body’s functions, no additional consideration of their biocompatibility is necessary. Similarly, due to their excellent biological activities, copper complexes have a special place in the pool of metalloporphyrins. A healthy human body contains trace amounts of copper which makes it biocompatible. This encouraged us to appraise the cumulative efforts on the biological applications of copper porphyrins. Here, we present the pertinent reflections in the field of biological agents, with a focus on DNA binding, photodynamic therapy, anticancer activity without irradiation, positron emission tomography, drug delivery systems, and antimicrobial activity with and without irradiation induced by distinct copper porphyrins with diverse substituents.
Alternative routes for 64Cu production using an 18 MeV medical cyclotron in view of theranostic applications
2023, Applied Radiation and Isotopes
Radiometals play a fundamental role in the development of personalized nuclear medicine. In particular, copper radioisotopes are attracting increasing interest since they offer a varying range of decay modes and half-lives and can be used for imaging (⁶⁰Cu, ⁶¹Cu, ⁶²Cu and ⁶⁴Cu) and targeted radionuclide therapy (⁶⁴Cu and ⁶⁷Cu), providing two of the most promising true theranostic pairs, namely ⁶¹Cu/⁶⁷Cu and ⁶⁴Cu/⁶⁷Cu. Currently, the most widely used in clinical applications is ⁶⁴Cu, which has a unique decay scheme featuring $β^{+}$ -, $β^{-}$ -decay and electron capture. These characteristics allow its exploitation in both diagnostic and therapeutic fields. However, although ⁶⁴Cu has extensively been investigated in academic research and preclinical settings, it is still scarcely used in routine clinical practice due to its insufficient availability at an affordable price. In fact, the most commonly used production method involves proton irradiation of enriched ⁶⁴Ni, which has a very low isotopic abundance and is therefore extremely expensive. In this paper, we report on the study of two alternative production routes, namely the ⁶⁵Cu(p,pn)⁶⁴Cu and ⁶⁷Zn(p, $α$ )⁶⁴Cu reactions, which enable low and high ⁶⁴Cu specific activities, respectively. To optimize the ⁶⁴Cu production, while minimizing the mass of copper used as a target in the first case, or the co-production of other copper radioisotopes in the second case, an accurate knowledge of the production cross sections is of paramount importance. For this reason, the involved nuclear reaction cross sections were measured at the Bern medical cyclotron laboratory by irradiating enriched ⁶⁵CuO and enriched ⁶⁷ZnO targets. On the basis of the obtained results, the production yield and purity were calculated to assess the optimal irradiation conditions. Several production tests were performed to confirm these findings.
Cross-section measurement for an optimized 61Cu production at an 18 MeV medical cyclotron from natural Zn and enriched 64Zn solid targets
2022, Applied Radiation and Isotopes
The availability of novel medical radionuclides is a key point in the development of personalised nuclear medicine. In particular, copper radioisotopes are attracting considerable interest as they can be used to label various molecules of medical interest, such as proteins and peptides, and offer two of the most promising true theranostic pairs, namely ⁶¹Cu/⁶⁷Cu and ⁶⁴Cu/⁶⁷Cu. Although ⁶⁴Cu (t $_{1 / 2}$ = 12.7006 h, $β^{+}$ : 17.6%, $β^{-}$ : 38.5%) is nowadays the most commonly used as a diagnostic radionuclide, ⁶¹Cu (t $_{1 / 2}$ = 3.339 h, $β^{+}$ : 61%) features more favourable nuclear properties, such as a higher positron decay fraction and the absence of $β^{-}$ emissions. To date, the production of ⁶¹Cu has been carried out irradiating highly enriched ⁶¹Ni targets with a low energy proton beam. However, the use of the very expensive ⁶¹Ni targets requires an efficient recovery of the target material and makes this method quite inconvenient. Another promising production route is the proton irradiation of natural Zn or enriched ⁶⁴Zn targets, exploiting the (p, $α$ ) nuclear reaction. Along this line, a research program is ongoing at the Bern medical cyclotron, equipped with an external beam transfer line and a solid target station. In this paper, we report on cross-section measurements of the ⁶⁴Zn(p, $α$ )⁶¹Cu nuclear reaction using natural Zn and enriched ⁶⁴Zn material, which served as the basis to perform optimized ⁶¹Cu production tests with solid targets.
Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives
2021, Coordination Chemistry Reviews
Citation Excerpt :
Interesting in vivo anticancer activity was exhibited by the cisplatin-gold functionalized-MWCNT against MCF-7 (human breast cancer cells) which was evidenced by an appreciably low IC50 value of 7.7 μM as compared to gold uncapped MWCNTs (IC50 = 11.7 μM). Mesoporous silica nanoparticles (MSNs) represent an emerging class of nanomaterials that have been extensively used as drug carriers for therapy and diagnosis by various research groups worldwide [224]. Owing to their unique features of MSNs that include biocompatibility, porous mesostructure, large surface to mass ratio, tunable pore size etc.
Coordination compounds on account of distinctive features of metal ions that include variable oxidation states, diverse range of geometries and coordination numbers, physiologically accessible redox states, and their tendency to coordinate with diverse organic ligands offer a versatile platform for the rational design of novel therapeutic and diagnostic metallodrugs. The prevalence of numerous diseased states which is attributed to either excess or deficiency of a metal ion in the living system validate the therapeutic potential of a metal ion and the related compounds. Although many empirical evidences pertaining to the therapeutic use of metals and their salt compounds have been reported since antiquity, nevertheless the fortuitous discovery of cisplatin served as a benchmark for the development of metallodrugs against several diseased states. Consequently, a vast library of metal compounds have been rationally designed and explored for diverse therapetutic applications viz., anticancer, antimicrobial, antiviral, antidiabetic, diagnosis, imaging, anti-neurodegenerative diseases etc. Notably, many of which have been approved as drugs for clinical use (both therapy and diagnosis) while some are at different stages of clinical trials. Given the wider scope of metallodrugs in the area of medicinal field, this review features a comprehensive overview of the advancements made in metallodrug regimens for the diagnosis and therapies. Various archetypal examples of potential metallodrugs which are currently in clinical use, at different stages of clinical trials or at preclinical development have been highlighted.
AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-A-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions
2021, Nuclear Medicine and Biology
Combining the advantages of both cyclic and acyclic chelator systems, AAZTA (1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-methylperhydro-1,4-diazepine) is well suited for complexation of various diagnostic and therapeutic radiometals such as gallium-68, scandium-44 and lutetium-177 under mild conditions. Due to its specificity for primary amines and pH dependent binding properties, squaric acid (SA) represents an excellent tool for selective coupling of the appropriate chelator to different target vectors. Therefore, the aim of this study was to evaluate radiolabeling properties of the novel bifunctional AAZTA⁵-SA being coupled to a model antibody (bevacizumab) in comparison to DOTA-SA, DTPA-p-Bn-SA and CHX-A″-DTPA-p-Bn-SA using the therapeutic nuclide lutetium-177.
As proof-of-concept, bevacizumab was first functionalized with AAZTA⁵-SA, DOTA-SA, DTPA-p-Bn-SA or CHX-A″-DTPA-p-Bn-SA. After purification via fractionated size exclusion chromatography (SEC), the corresponding immunoconjugates were subsequently radiolabeled with lutetium-177 at pH 7 and room temperature (RT) as well as 37 °C. After 90 min, labeling of AAZTA⁵-SA-mAb resulted in almost quantitative radiochemical yields (RCY) of >98% and >99%, respectively. Formation of [¹⁷⁷Lu]Lu-DTPA-p-Bn-SA-mAb indicated rapid labeling kinetics reaching similar yields at RT already after 30 min. Fast but incomplete radiolabeling of the CHX-A″-analogue could be observed with a yield of 74% after 10 min and no further significant increase. In contrast, ¹⁷⁷Lu-labeling of DOTA-SA-mAb showed negligible radiochemical yields of <2% both at room temperature and 37 °C. In vitro complex stability measurements of [¹⁷⁷Lu]Lu-AAZTA⁵-SA-mAb at 37 °C indicated >94% protein bound activity in human serum and >92% in phosphate buffered saline (PBS), respectively within 15 days. [¹⁷⁷Lu]Lu-DTPA-p-Bn-SA-mAb and [¹⁷⁷Lu]Lu-CHX-A″-DTPA-p-Bn-SA-mAb revealed similar to even slightly higher in vitro stability in both media.
Coupling of AAZTA⁵-SA to the monoclonal antibody bevacizumab allowed for ¹⁷⁷Lu-labeling with almost quantitative radiochemical yields both at room temperature and 37 °C. Within 15 days, the resulting radioconjugate indicated very high in vitro complex stability both in human serum and PBS. Therefore, AAZTA⁵-SA is a promising tool for ¹⁷⁷Lu-labeling of sensitive biomolecules such as antibodies for theranostic applications.
Radiochemistry: A Hot Field with Opportunities for Cool Chemistry
2023, ACS Central Science

View all citing articles on Scopus

View full text

Copper radionuclides and radiopharmaceuticals in nuclear medicine

Abstract

Nucl. Med. Biol.

Int. J. Radiat. Oncol. Biol. Phys.

Appl. Radiat. Isot.

Nucl. Med. Biol.

Coord. Chem. Rev.

Appl. Radiat. Isot.

Appl. Radiat. Isot.

Bioinorg. Chem.

Nucl. Med. Biol.

Nucl. Med. Biol.

Nucl. Med. Biol.

Biochem. Biophys. Res. Commun.

Appl. Radiat. Isot.

Nucl. Med. Biol.

Appl. Radiat. Isot.

Nucl. Med. Biol.

J. Pharm. Sci.

J. Biol. Chem.

J. Biol. Chem.

Coord. Chem. Rev.

Copper radiosensitizers

Lethal effects of the complex of bleomycin with high specific activity 64Cu on Ehrlich ascites tumour cells

Annu. Rep. Res. Reactor Inst. Kyoto Univ.

Copper-64-labeled antibodies for PET imaging

J. Nucl. Med.

Optimization of the preparation of Cu-64-labeled monoclonal antibody (MAb) fragments (1A3-F(ab′)2) for improved biodistribution

J. Nucl. Med.

Initial comparison of Cu-67 and Cu-64-labeled anti-colorectal carcinoma Mab 1A3 as agents for radioimmunotherapy in tumor-bearing hamsters

J. Nucl. Med.

Cu-64-TETA-D-Phe-1-Octreotide: A positron emitting somatostatin receptor imaging agent with receptor binding and renal clearance similar to In-111-DTPA-D-Phe-1-Octreotide

J. Nucl. Med.

Biodistribution in a tumorbearing animal model and metabolism of two Cu-64-labeled octreotide analogs

J. Nucl. Med.

Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab′)2

J. Nucl. Med.

In vitro and in vivo evaluation of copper-64-octreotide conjugates

J. Nucl. Med.

Comparison of radioimmunotherapy (RIT) in colorectal tumor-bearing hamsters with Cu-64 and Cu-67-labeled Mab 1A3

J. Nucl. Med.

Immobile- and mobile-phase ESR spectroscopy of copper complexes: Studies on biologically interesting bis(thiosemicarbazonato) copper(II) chelates

Inorg. Chem.

Crystal structures of tetrahydro borato(1,4,8,11-tetraazacyclotetradecane)copper(II) CuC10H24N4(BH4)2 and (5,7,12,14-tetramethyl-1,4,8,11-tetraazacyclononane)copper(II) CuC14H32N4(BH4)2

Koord. Khim.

Distribution of copper-64 in control mice and in mice bearing ascites Krebs tumor cells

Cancer Res.

Differences in the consequences of the decay of radioactive 64Cu atoms incorporated in cells under either in vitro or in vivo conditions

Radiat. Environ. Biophys.

Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, 64Cu and 67Cu

Int. J. Radiat. Biol.

An evaluation of Cu-64 pyruveldehyde bis(methylthiosemicarbazone) (PTSM) for the measurement of tissue perfusion

J. Nucl. Med.

Copper-64 as a radiopharmaceutical for canine prostate imaging

Subcellular distribution of tissue radiocopper following intravenous administration of 67 Cu-labeled Cu-PTSM

Nucl. Med. Biol.

Examination of the effects of glutathione depletion on Cu(PTSM) biodistribution

J. Nucl. Med.

Evaluation of Copper-62 PTSM as a myocardial flow tracer

J. Nucl. Med.

The kinetics of copper-62-PTSM in the normal human heart

J. Nucl. Med.

Evidence for a square scheme involving conformational intermediates in electron-transfer reactions of copper(II) systems

J. Am. Chem. Soc.

Phosphines and metal phosphine complexes: Relationship of chemistry to anticancer and other biological activity

Struct. Bonding

A comparison of copper uptake by liver plasma membrane vesicles and uptake by isolated cultured rat hepatocytes

Hepatology

Cu-67-Anti-CEA MAB, a potential therapeutic agent: Biokinetic studies in patients with colon carcinoma

J. Nucl. Med.

Circulating ceruloplasmin is an important source of copper for normal and malignant animal cells

Biochim. Biophys. Acta

Dosimetry of copper radionuclides

J. Nucl. Med.

Evaluation of Cu-67 and Sm-153 immunoconjugates for tumor therapy

J. Nucl. Med.

Biliary excretion of 203Hg, 65Cu, 52Mn and 210Pb in the rat

Br. J. Ind. Med.

A new conformation and co-ordination mode for 1,4,7-trithiacyclo-nonane (9S3): Structure of [Cu2(9S3)3],(BF4)2 · H2O

J. Chem. Soc. Chem. Commun.

Lethal effects of the complex of bleomycin with high specific activity ⁶⁴Cu on Ehrlich ascites tumour cells

Optimization of the preparation of Cu-64-labeled monoclonal antibody (MAb) fragments (1A3-F(ab′)₂) for improved biodistribution

Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab′)₂

Crystal structures of tetrahydro borato(1,4,8,11-tetraazacyclotetradecane)copper(II) CuC₁₀H₂₄N⁴(BH₄)₂ and (5,7,12,14-tetramethyl-1,4,8,11-tetraazacyclononane)copper(II) CuC₁₄H₃₂N₄(BH₄)₂

Differences in the consequences of the decay of radioactive ⁶⁴Cu atoms incorporated in cells under either in vitro or in vivo conditions

Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, ⁶⁴Cu and ⁶⁷Cu

Subcellular distribution of tissue radiocopper following intravenous administration of ⁶⁷ Cu-labeled Cu-PTSM

Biliary excretion of ²⁰³Hg, ⁶⁵Cu, ⁵²Mn and ²¹⁰Pb in the rat

A new conformation and co-ordination mode for 1,4,7-trithiacyclo-nonane (9S3): Structure of [Cu₂(9S3)₃],(BF₄)₂ · H₂O